Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Questionnaire

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00706875Completed

A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors

NCT00588276Phase 1Completed

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

Showing all 2 trials

Research Network

Common Treatments

  • Questionnaire1
  • 124iiodoazomycin Galactopyranoside1

Active Sponsors

  • Memorial Sloan Kettering Cancer Center2
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Uterine Cancer2
  • Renal Cancer1
  • Cervical Cancer1
  • Heent Cancer1
  • Rectum1

Activity Timeline